Atypical femoral fractures: Epidemiology, etiology, and patient management

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 3, 2012, Pages 348-354

  Donnelly, Eve ^a   Saleh, Anas ^b   Unnanuntana, Aasis ^c   Lane, Joseph M ^b  

^a Cornell University   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atypical fracture; Bisphosphonate; Diaphyseal fracture; Osteoporosis; Subtrochanteric fracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE TUMOR; FEMUR FRACTURE; HUMAN; INCIDENCE; METABOLIC BONE DISEASE; PATHOLOGY; REVIEW; TIME; UNITED STATES;

BONE DISEASES, METABOLIC; BONE NEOPLASMS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; INCIDENCE; TIME FACTORS; UNITED STATES;

EID: 84868341331     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283552d7d     Document Type: Review

References (40)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541.
2. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004; 19:11-18.
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedro-nate Therapy (VERT) Study Group. JAMA 1999; 282:1344-1352.
4. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927-2938.
5. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267-2294.
6. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
7. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-350.
8. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364:1728-1737.
9. Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010; 21:399-408.
10. Ng AC, Drake MT, Clarke BL, et al. Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. Osteoporos Int 2011. doi: 10.1007/s00198-011-1777-9. [Epub ahead of print]
11. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011; 26:553-560.
12. Feldstein A, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27:977-986.
13. Puhaindran ME, Farooki A, Steensma MR, et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011; 93:1235-1242.
14. Dell R, Greene D, Ott S, et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. J Bone Miner Res 2011; 25 (Suppl. 1):1201.
15. Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bispho-sphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011; 48: 966-971.
16. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362:1761-1771.
17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24:1095-1102.
18. Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011; 26:993-1001.
19. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305:783-789.
20. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011; 22:2951-2961.
21. Koh JS, Goh SK, Png MA, et al. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 2011; 52:77-80.
22. Unnanuntana A, Ashfaq K, Ton QV, et al. The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 2012; 470:291-298.
23. Tang SY, Allen MR, Phipps R, et al. Changes in nonenzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20:887-894.
24. Gourion-Arsiquaud S, Allen MR, Burr DB, et al. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 2010; 46:666-672.
25. Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012; 27:672-678.
26. Tjhia CK, Odvina CV, Rao DS, et al. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011; 49: 1279-1289.
27. Donnelly E, Meredith DS, Nguyen JT, et al. Bone tissue composition varies across anatomic sites in the proximal femur and the iliac crest. J Orthop Res 2012; 30:700-706.
28. Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007; 22:1759-1765.
29. Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39:872-879.
30. Brennan O, Kennedy OD, Lee TC, et al. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res 2011; 29:419-424.
31. Waterman GN, Yellin O, Jamshidinia K, et al. Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases. J Bone Joint Surg Am 2011; 93:e106(1)-e106(9).
32. Kidd LJ, Cowling NR, Wu AC, et al. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res 2011; 29:1827-1833.
33. Sloan AV, Martin JR, Li S, et al. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 2010; 47:235-240.
34. Weil YA, Rivkin G, Safran O, et al. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 2011; 71:186-190.
35. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-751.
36. Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011; 96:1627-1632.
37. Ha YC, Cho MR, Park KH, et al. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 2010; 468:3393-3398.
38. Banffy MB, Vrahas MS, Ready JE, et al. Nonoperative versus prophylactic treatment of bisphosphonate-Associated femoral stress fractures. Clin Orthop Relat Res 2011; 469:2028-2034.
39. Summary Minutes of the Joint Meeting of the Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee, 9 September 2011. 2011. http://www.fda.gov/AdvisoryCommit tees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisory Committee/ucm262537.htm.
40. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305:783-789.